These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3809188)

  • 1. Statistical analysis techniques and sample size determination for clinical trials of treatments for bladder cancer.
    Byar D; Kaihara S; Sylvester R; Freedman L; Hannigan J; Koiso K; Oohashi Y; Tsugawa R
    Prog Clin Biol Res; 1986; 221():49-64. PubMed ID: 3809188
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of bladder cancer recurrences].
    Zak BI; Abrazheev VG; Vakulina TI
    Vopr Onkol; 1977; 23(11):47-50. PubMed ID: 339535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardization of format of reporting results.
    Dalesio O; Barton B; Hisazumi H; Hilgar A; Staquet M; Tagnon H; Uyama T
    Prog Clin Biol Res; 1986; 221():15-31. PubMed ID: 3809181
    [No Abstract]   [Full Text] [Related]  

  • 4. Rationals for optimizing bladder cancer treatment and control.
    Wolf H
    Scand J Urol Nephrol Suppl; 1989; 125():103-6. PubMed ID: 2699070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG in the management of superficial bladder cancer.
    Robinson MR
    Prog Clin Biol Res; 1985; 185B():161-6. PubMed ID: 3898140
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel therapeutics for patients with non-muscle-invasive bladder cancer.
    Svatek RS; Kamat AM; Dinney CP
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):807-13. PubMed ID: 19496717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of locally recurrent invasive bladder cancer following radical cystectomy.
    Pisters LL; Westney L
    Semin Urol Oncol; 1996 May; 14(2):112-9. PubMed ID: 8734739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodology of superficial bladder cancer trials: objective evaluation of treatment - the need for standardization.
    Bassi PF; Volpe A; Racioppi M; D'Agostino D; Gardi M; Totaro A; Pinto F; Sacco E; Bongiovanni L
    Urol Int; 2009; 83(3):258-63. PubMed ID: 19829021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bladder-sparing procedure as good as cystectomy for treating invasive bladder cancer.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Aug; 13(15):7-9. PubMed ID: 12553324
    [No Abstract]   [Full Text] [Related]  

  • 11. Current trends in bladder cancer treatment.
    Lamm DL; Allaway M
    Ann Chir Gynaecol; 2000; 89(3):234-41. PubMed ID: 11079794
    [No Abstract]   [Full Text] [Related]  

  • 12. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.
    Jain A; Phillips RM; Scally AJ; Lenaz G; Beer M; Puri R
    Urology; 2009 May; 73(5):1083-6. PubMed ID: 19232688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial intelligence for predicting recurrence-free probability of non-invasive high-grade urothelial bladder cell carcinoma.
    Cai T; Conti G; Nesi G; Lorenzini M; Mondaini N; Bartoletti R
    Oncol Rep; 2007 Oct; 18(4):959-64. PubMed ID: 17786360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer of the urinary bladder: prognosis of the outcome].
    Zimichev AA; Prianichnikova MB; Maklakov VN
    Urologiia; 2009; (3):52-3. PubMed ID: 19673123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
    Prout GR; Kopp J
    Prog Clin Biol Res; 1984; 162B():397-427. PubMed ID: 6438644
    [No Abstract]   [Full Text] [Related]  

  • 16. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
    Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
    Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superficial TCC bladder cancer: the impact of tumor differentiation on recurrence, progression and survival.
    Kurth KH
    Prog Clin Biol Res; 1984; 162A():307-18. PubMed ID: 6483914
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical radiobiology of stage T2-T3 bladder cancer.
    Majewski W; Maciejewski B; Majewski S; Suwinski R; Miszczyk L; Tarnawski R
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):60-70. PubMed ID: 15337540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Superficial bladder tumors. Preliminary results of a prospective study comparing endovesical BCG, adriamycin and thio-tepa].
    Martínez-Piñeiro JA; de la Peña J; Hidalgo L; Cisneros J; Jiménez León J; Machuca J; Perdices C
    Arch Esp Urol; 1985; 38(6):545-53. PubMed ID: 3938633
    [No Abstract]   [Full Text] [Related]  

  • 20. The optimal management of T1G3 bladder cancer.
    Emiliozzi P; Pansadoro A; Pansadoro V
    BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.